SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-188625
Filing Date
2022-07-06
Accepted
2022-07-06 16:31:00
Documents
12
Period of Report
2022-07-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d268226d8k.htm   iXBRL 8-K 25383
  Complete submission text file 0001193125-22-188625.txt   147358

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvs-20220706.xsd EX-101.SCH 2878
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20220706_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20220706_pre.xml EX-101.PRE 11276
6 EXTRACTED XBRL INSTANCE DOCUMENT d268226d8k_htm.xml XML 3350
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 221069146
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences